FDA Grants Breakthrough Therapy Designation for Genentech’s Alecensa® (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
Bill Gross' departure and the subsequent outflows have not changed the management process of PIMCO Total Return, says PIMCO's Mark Kiesel.
NO OFFER, INVESTMENT ADVICE, OR PERFORMANCE GUARANTEES All written content is for informational purposes only and may not constitute a complete description of available investment services or performance. Neither the information nor any opinion expressed constitutes an offer by IronHorse to buy or ...
Investors should be cautious of rapid inflows into high-yield and bank-loan funds as managers could have difficulty putting excess money to work in high-conviction ideas.
A great deal of misunderstanding surrounds the risks and opportunities of credit default swaps.